Key TakeawaysXenon filed an NDA with the FDA for azetukalner to treat focal seizures, potentially its first marketed therapyNew enrollment in depression and bipolar disorder studies was halted following neuropsychiatric safety concernsShares of XENE plummeted 25% to $42.84 during premarket hours on FridayNeedham reduced its target price from $78 to $60 while maintaining a Buy recommendation; Deutsche Bank moved to Hold with a $46 targetWells Fargo maintained its Overweight stance, stating the epilepsy program remains unaffectedXenon Pharmaceuticals submitted a New Drug Application for azetukalner targeting focal seizures on Thursday, representing a critical milestone that could deliver the biotech company’s inaugural commercial therapy. However, the positive development was rapidly eclipsed by troubling safety data.Simultaneously with the NDA filing, Xenon disclosed that it had suspended new participant enrollment across ongoing studies evaluating major depressive disorder and bipolar depression. The decision followed observations of elevated frequencies of neuropsychiatric adverse reactions, spanning confusion, excessive drowsiness, coordination problems, and isolated instances of psychotic episodes.Xenon Pharmaceuticals Inc., XENEShares of XENE collapsed 25% to $42.84 before the market opened on Friday. Should these losses persist through the session, it would represent the stock’s most severe single-day decline since March 2017, when shares plummeted a record 53%. The price would also hit its lowest level in half a year.The company explained that while the adverse reactions aligned with azetukalner’s established safety characteristics, they had not emerged during previous clinical assessments. Xenon characterized the enrollment suspension as a likely temporary and precautionary action.The biotechnology firm indicated it would explore adjusted dosing strategies, potentially incorporating gradual dose escalation or reduced maximum doses, to enhance patient tolerance before restarting recruitment efforts.Analyst Community Divided on OutlookDavid Hoang of Deutsche Bank downgraded XENE from Buy to Hold status and dramatically reduced his price objective from $90 to $46. His rationale centered on concerns that the development undermines azetukalner’s competitive positioning as a frontline focal epilepsy treatment option.In contrast, Wells Fargo analyst Benjamin Burnett maintained his Overweight recommendation. He expressed confidence that the psychiatric trial interruption carries no implications for the focal onset seizures development program.Needham analysts lowered their price objective from $78 to $60 while preserving a Buy rating. The investment firm eliminated all revenue forecasts related to major depressive disorder and bipolar disorder indications from its azetukalner financial modeling.Needham highlighted lingering questions about whether modified dosing approaches can successfully mitigate neuropsychiatric complications without compromising therapeutic efficacy to clinically meaningful levels.Development Program Status and Future PlansPrior to the enrollment halt, the X-NOVA2 phase 3 study in major depressive disorder had recruited 80% of its planned 450-participant cohort. Topline data from this trial is anticipated during the first quarter of 2027.The company stated it will make determinations regarding potential resumption of the depression and bipolar disorder development programs following the X-NOVA2 data release.H.C. Wainwright retained a Buy recommendation with a $74 price objective, highlighting that FDA reviewers raised no concerns about insufficient drug exposure levels during pre-submission discussions for the epilepsy application.Xenon’s balance sheet shows a net cash position. According to InvestingPro analysis, the stock’s intrinsic value stands at $52.77, indicating shares were trading above fundamental value even prior to Friday’s selloff.Wall Street consensus does not anticipate Xenon achieving profitability during the current fiscal year. Prior to Thursday’s announcement, the stock had appreciated 52% over the trailing twelve-month period.Needham’s updated $60 price target exclusively reflects azetukalner’s commercial opportunity in epilepsy, completely excluding any contribution from psychiatric disorder applications.The post Xenon Pharmaceuticals (XENE) Plunges 25% on Psychiatric Trial Halt: Is Now the Time to Buy? appeared first on Blockonomi.